| Exclusion Criteria: | 1) History of another primary malignancy that has not been in remission for at least 3 years (The following are exempt from the three-year limit: non-melanoma skin cancer, fully excised melanoma in situ [Stage 0], curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Papanicolau [PAP] smear.)
2) Current diagnosis of primary cutaneous ALCL (patients who have transformed to systemic ALCL are eligible), mycosis fungoides, Sezary syndrome or other primary cutaneous lymphomas; extranodal NK/T-cell lymphoma, nasal type
3) Known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy (PML)
4) Left ventricular ejection fraction< 45% or symptomatic cardiac disease (including symptomatic ventricular dysfunction, symptomatic coronary artery disease, and symptomatic arrhythmias), or myocardial infarction within the past 6 months
5) Any active Grade 3 or higher viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin
6) Known human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus positive status
7) Females who are pregnant or lactating
8) Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin or any component of CHOP |